We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+52.84%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$545M
AUM Growth
+$88.9M
Cap. Flow
-$58.1M
Cap. Flow %
-10.67%
Top 10 Hldgs %
76.47%
Holding
25
New
8
Increased
4
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$21.9M
2
XFOR icon
X4 Pharmaceuticals
XFOR
+$21.1M
3
IVVD icon
Invivyd
IVVD
+$16.1M
4
MNPR icon
Monopar Therapeutics
MNPR
+$13.9M
5
IMMX icon
Immix Biopharma
IMMX
+$12.3M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$23.4M
2
COGT icon
Cogent Biosciences
COGT
+$22.7M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$20.2M
4
MRUS
Merus
MRUS
+$17.3M
5
LENZ
LENZ Therapeutics
LENZ
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$11.2B
$87.5M 16.07%
649,179
-152,045
-19% -$16.6M
AMLX icon
2
Amylyx Pharmaceuticals
AMLX
$2.17B
$54.3M 9.97%
4,496,487
-108,391
-2% -$1.47M
COGT icon
3
Cogent Biosciences
COGT
$6.91B
$43.2M 7.93%
1,217,064
-807,977
-40% -$22.7M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$16B
$42.2M 7.74%
248,070
-52,540
-17% -$8.05M
PCVX icon
5
Vaxcyte
PCVX
$8.01B
$36.9M 6.77%
798,940
+10,499
+1% +$470K
DYN icon
6
Dyne Therapeutics
DYN
$4.24B
$35M 6.42%
1,788,616
-885,853
-33% -$16.8M
PHVS icon
7
Pharvaris
PHVS
$2.37B
$31.6M 5.81%
1,140,033
+253,701
+29% +$6.11M
CELC icon
8
Celcuity
CELC
$4.01B
$31.6M 5.8%
317,095
-156,733
-33% -$12.9M
ALMS
9
Alumis Inc
ALMS
$3.45B
$30.6M 5.62%
+3,135,953
New +$21.9M
IRON icon
10
Disc Medicine
IRON
$2.85B
$23.7M 4.35%
298,429
-42,468
-12% -$3.59M
XFOR icon
11
X4 Pharmaceuticals
XFOR
$372M
$23.2M 4.26%
+5,800,530
New +$21.1M
MNPR icon
12
Monopar Therapeutics
MNPR
$739M
$21.3M 3.9%
325,701
+170,331
+110% +$13.9M
IVVD icon
13
Invivyd
IVVD
$180M
$19.1M 3.51%
+7,735,386
New +$16.1M
OCUL icon
14
Ocular Therapeutix
OCUL
$1.89B
$18.3M 3.35%
1,504,880
+353,194
+31% +$4.29M
IMMX icon
15
Immix Biopharma
IMMX
$619M
$15.7M 2.88%
+2,999,169
New +$12.3M
OCS icon
16
Oculis Holding
OCS
$665M
$10.3M 1.89%
+516,761
New +$10.3M
IKT icon
17
Inhibikase Therapeutics
IKT
$369M
$7.91M 1.45%
+3,856,799
New +$6.14M
CNTA
18
DELISTED
Centessa Pharmaceuticals
CNTA
$7.07M 1.3%
282,692
-451,847
-62% -$11.4M
OVID icon
19
Ovid Therapeutics
OVID
$439M
$4.08M 0.75%
+2,500,000
New +$3.85M
IVA
20
Inventiva
IVA
$1.09B
$1.32M 0.24%
+283,166
New +$1.32M
CGON icon
21
CG Oncology
CGON
$6.48B
– –
-579,895
Closed -$23.4M
MRUS
22
DELISTED
Merus
MRUS
– –
-184,135
Closed -$17.3M
NAMS icon
23
NewAmsterdam Pharma
NAMS
$3.53B
– –
-153,147
Closed -$4.36M
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.36B
– –
-503,701
Closed -$20.2M
LENZ
25
LENZ Therapeutics
LENZ
$179M
– –
-368,176
Closed -$17.1M

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $553M AUM 26.47% 1-Year Est. Return

Saturn V Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Saturn V Capital Management held 25 positions worth $545M, up 20% from $456M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Saturn V Capital Management withdrew a net $58.1M in Q4 2025, closing 5 positions and reducing 8 holdings. Its most notable exit was CG Oncology, an estimated $23.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Saturn V Capital Management opened a new position in Alumis Inc worth $30.6M.

  • Saturn V Capital Management's largest Q4 2025 buy was Alumis Inc: 3,135,953 shares worth $30.6M.
  • Saturn V Capital Management added most to Monopar Therapeutics in Q4 2025, an estimated $13.9M increase.
  • Saturn V Capital Management's biggest Q4 2025 reduction was Cogent Biosciences, cutting an estimated $22.7M.
  • Saturn V Capital Management fully exited CG Oncology in Q4 2025, selling an estimated $23.4M.
  • Saturn V Capital Management's ten largest holdings make up 76% of its $545M portfolio in Q4 2025.
  • Saturn V Capital Management opened 8 new positions and closed 5 in Q4 2025.
  • Saturn V Capital Management's portfolio value rose 20% quarter-over-quarter to $545M.

Based on Saturn V Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.